Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Recurrence 16Burkitt Lymphoma 13Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 5Leukemia 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nausea 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Brain Neoplasms 3Renal Insufficiency 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2

Interventions

siltuximab 2tocilizumab 1talquetamab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytokine Release Syndrome × Dexamethasone × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡